Endo Health Solutions (ENDP) Inactive 10-Q2011 Q1 Quarterly report

Filed: 29 Apr 11, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. sophomore Avg

New words: adding, Apax, array, assist, ASU, backstopped, Baton, begun, bitartrate, bridge, canceled, carcinogenicity, cardiac, Catholic, Cincinnati, CNS, coast, companywide, confident, conform, dean, debate, debated, declaration, declared, defund, discipline, disorder, distributor, downturn, dyskinesia, earthquake, East, economy, emerging, essentially, Fargo, FASB, Fenner, forecasted, FortestaTM, gave, geological, hand, Humana, immunosuppression, indirect, infrastructure, inline, instance, intensify, Jury, leader, legacy, lending, lifelong, Louisiana, Lynch, merge, Merrill, mix, movement, multicurrency, municipal, Mylan, Nash, NIKA, Noramco, northeast, nuclear, null, obsolescence, Ohio, oily, opportunity, optimize, overdose, overturn, Parent, Parish, pediatric, pelvic, Philadelphia, Pierce, proportion, propoxyphene, rata, ratably, region, reinstated, reinstatement, reject, repeal, reuse, Rouge, Royal, Rx, School, Secretary, semiannually, Smith, solid, Southeast, spread, Stanley, streamline, Superior, surviving, swap, swing, syndicate, tardive, toxicity, transparency, tsunami, unconstitutional, unintentional, unrestricted, unsecured, unsolicited, UrocidinTM, vacancy, void, wholly, wide, widely, workplace, worksite, world, Zydone

Removed: absorb, accelerate, accountability, accrue, acetate, Adamczyk, agonist, allocate, altered, amine, amortize, androgen, anomaly, approve, Argentina, assign, Australia, Aveed, Bachelor, biocompatibility, biotech, Biotechnology, block, bond, build, callable, capability, carcinomain, categorized, Centocor, CEO, Chancery, children, CIS, clinically, Clive, comfort, competing, compound, compounded, conclusive, constant, constituted, continuously, CPP, credited, default, defending, Delatestryl, Denmark, depending, derivative, direct, disagreement, dismissal, dispensed, donut, earned, element, embark, employee, enanthate, enforceable, enhanced, enterprise, EPS, equally, Europe, evolve, excellent, exercising, expiry, FDC, fertilization, fifty, file, final, flexible, fluid, Fortesta, Foundation, freestanding, frequency, GH, GlaxoSmithKline, GnRH, histrelin, hole, holiday, Hong, hormone, hundred, IIb, impaired, implantation, impurity, incontinence, injection, instillation, insufficient, Interbank, intramuscular, intravesical, Ireland, Italy, Johnson, joining, Joseph, Julie, Kingdom, Kong, legally, likelihood, List, lived, London, lowest, luteinizing, Malaysia, matured, McHugh, Meanwell, mentioned, met, methodology, Mississippi, Nathaniel, natural, Nebido, Nora, OAB, octapeptide, oil, onset, overactive, parenteral, partial, performed, pregnancy, presently, prevented, problem, pronouncement, quaternary, rating, receipt, reconsider, recouped, recur, recurrent, reelection, reintroduce, releasing, renamed, renew, repaid, replicate, replicating, reservoir, residual, resolved, respond, restructure, retention, retrievable, role, Saint, Sanofi, Science, scope, secure, seeking, serve, setting, shared, sharing, short, shortage, shortfall, side, Singapore, Smeal, SmithKline, soft, solution, somatostatin, Spain, spectrum, split, stand, stated, sterile, stuttering, succeeding, summarized, supplementing, sustained, Taiwan, targeted, Thailand, thereunder, traditionally, treat, treated, unacceptable, undecanoate, understanding, unfavorable, unfunded, unprecedented, urge, urgency, urinary, Urocidin, Valeant, valrubicin, venture, Vice, VIE, Virology, week, worth, Zealand

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

ENDP similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Alan G. Levin, as Chief Financial Officer of Endo Pharmaceuticals Holdings Inc. (the Company), hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Quarterly Report on Form 10-Q of the Company for the quarterly period ended March 31, 2011 (the Report) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m); and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


		/S/ ALAN G. LEVIN
Name:		Alan G. Levin
Title:		Executive Vice President, Chief Financial Officer (Principal Financial Officer)

Date: April 29, 2011

A signed original of this written statement required by Section 906 has been provided to, and will be retained by, Endo Pharmaceuticals Holdings Inc. and furnished to the Securities and Exchange Commission or its staff upon request.